Skip to main content
PMC home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2009 Feb 3;22(Suppl 6):VI-2–VI-12. doi: 10.1002/clc.4960221703

Trials of glycoprotein IIb‐IIIa inhibitors in non‐st‐segment elevation acute coronary syndromes: Applicability to the practice of medicine in the united states

M Cohen 1, J J Ferguson III 2, R A Harrington 3
PMCID: PMC6655356  PMID: 10526702

Abstract

Platelet‐mediated thrombosis has been recognized as the primary pathophysiologic mechanism of acute coronary syndromes (ACS) and acute complications of percutaneous coronary intervention (PCI). Despite the clinical efficacy of the two most widely used antithrombotic agents, aspirin and heparin, each of them has significant therapeutic limitations. As a result, thrombosis and clinical events may occur despite the use of aspirin and heparin. The discovery that the platelet glycoprotein (GP) IIb‐IIIa represents the final common pathway to platelet aggregation and the growing recognition of the key role of platelets in the progression of thrombosis prompted the development of several GP IIb‐IIIa inhibitors as a potentially more effective form of antithrombotic therapy. Numerous trials of various GP IIb‐IIIa inhibitors as adjuncts to PCI have strongly supported this hypothesis. The subject of this supplement is the review of more recent evaluations of GP IIb‐IIIa inhibitors in the context of various treatment strategies for the management of patients with unstable angina or non‐ST‐segment elevation myocardial infarction, collectively known as non‐ST‐segment elevation ACS. Appropriate translation of these trials into clinical practice requires not only the knowledge of the trials' results but also the understanding of the design of individual studies, most notably the entry criteria and patient management strategies.

Keywords: acute coronary syndromes, percutaneous coronary intervention, myocardial infarction, glycoprotein IIb‐IIIa inhibitors, ST‐segment and non‐ST‐segment acute coronary syndromes, myocardial infarction

Full Text

The Full Text of this article is available as a PDF (1.4 MB).

References

  • 1. Armstrong PW, Fu Y, Chang WC, Topol EJ, Granger CB, Betriu A, Van de Werf F, Lee KL, Califf RM: Acute coronary syndromes in the GUSTO‐IIb trial: Prognostic insights and impact of recurrent ischemia. Circulation 1998; 98: 1860–1868 [DOI] [PubMed] [Google Scholar]
  • 2. Fuster V, Badimon L, Badimon JJ, Chesebro JH: The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 326: 242–250; 310–318 [DOI] [PubMed] [Google Scholar]
  • 3. Ambrose JA, Weinrauch M: Thrombosis in ischemic heart disease. Arch Intern Med 1996; 156: 1382–1394 [PubMed] [Google Scholar]
  • 4. Davies MJ: The role of plaque pathology in coronary thrombosis. Clin Cardiol 1997; 20 (suppl I, Intn'l): I–2–I–7 [Google Scholar]
  • 5. Wilson JM, Silberman H, Ferguson JJ: Abrupt vascular closure. J Invas Cardiol 1994; 6: 306–313 [PubMed] [Google Scholar]
  • 6. Coller BS: Platelets in cardiovascular thrombosis and thrombolysis In The Heart and Cardiovascular System: Scientific Foundations, 2nd Edition, p. 219–273 (Eds. Fozzard HA, Haber E, Jennings RB, Katz AM, Morgan HE.). New York: Raven Press, 1992. [Google Scholar]
  • 7. Lefkovits J, Plow EF, Topol EJ: Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332: 1553–1559 [DOI] [PubMed] [Google Scholar]
  • 8. Mizuno K, Satomura K, Miyamoto A, Arakawa K, Shibuya T, Arai T, Kurita A, Nakamura H, Ambrose JA: Angioscopic evaluation of coronary‐artery thrombi in acute coronary syndromes. N Engl J Med 1992; 326: 287–291 [DOI] [PubMed] [Google Scholar]
  • 9. The TIMI IIIB Investigators: Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non‐Q‐wave myocardial infarction: Results of the TIMI IIIB trial. Circulation 1994; 89: 1545–1556 [DOI] [PubMed] [Google Scholar]
  • 10. Théroux P, Ouimet H, McCans J, Latour J‐G, Joly P, Lévy G, Pelletier E, Juneau M, Stasiak J, deGuise P, Pelletier G, Rinzler D, Waters D: Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319: 1105–1111 [DOI] [PubMed] [Google Scholar]
  • 11. Cohen M, Adams PC, Parry G, Xiong J, Chamberlain D, Wieczorek I, Fox KAA, Chesebro JH, Strain J, Keller C, Kelly A, Lancaster G, Ali J, Kronmal R, Fuster V, and The Antithrombotic Therapy in Acute Coronary Syndromes Research Group : Combination antithrombotic therapy in unstable rest angina and non‐Q‐wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Circulation 1994; 89: 81–88 [DOI] [PubMed] [Google Scholar]
  • 12. Oler A, Whooley M, Oler J, Grady D: Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta‐analysis. J Am Med Assoc 1996; 276: 811–815 [PubMed] [Google Scholar]
  • 13. The GUSTO IIb Investigators: A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996; 335: 775–782 [DOI] [PubMed] [Google Scholar]
  • 14. Cohen M, Demers C, Gurfinkel EP, Turpie AGG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KAA, Premmereur J, Bigonzi F: A comparison of low‐molecular‐weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997; 337: 447–452 [DOI] [PubMed] [Google Scholar]
  • 15. The PARAGON Investigators : International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Circulation 1998; 97: 2386–2395 [DOI] [PubMed] [Google Scholar]
  • 16. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM‐PLUS) Study Investigators : Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non‐Q‐wave myocardial infarction. N Engl J Med 1998; 338: 1488–1497 [DOI] [PubMed] [Google Scholar]
  • 17. The PURSUIT Trial Investigators : Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339: 436–443 [DOI] [PubMed] [Google Scholar]
  • 18. Almony GT, Lefkovits J, Topol EJ: Antiplatelet and anticoagulant use after myocardial infarction. Clin Cardiol 1996; 19: 357–365 [DOI] [PubMed] [Google Scholar]
  • 19. The EPIC Investigators : Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high‐risk coronary angioplasty. N Engl J Med 1994; 330: 956–961 [DOI] [PubMed] [Google Scholar]
  • 20. The EPILOG Investigators : Platelet glycoprotein IIb/IIa receptor blockade and low‐dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689–1696 [DOI] [PubMed] [Google Scholar]
  • 21. The CAPTURE Investigators : Randomised placebo‐controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997; 349: 1429–1435 [PubMed] [Google Scholar]
  • 22. The EPISTENT Investigators : Randomised placebo‐controlled and balloon‐angioplasty‐controlled trial to assess safety of coronary stenting with use of platelet glycoprotein‐IIb/IIIa blockade. Lancet 1998; 352: 87–92 [DOI] [PubMed] [Google Scholar]
  • 23. The IMPACT‐II Investigators : Randomised placebo‐controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT‐II. Lancet 1997; 349: 1422–1428 [PubMed] [Google Scholar]
  • 24. The RESTORE Investigators : Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96: 1445–1453 [DOI] [PubMed] [Google Scholar]
  • 25. The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators : A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338: 1498–1505 [DOI] [PubMed] [Google Scholar]
  • 26. Harrington RA, Kleiman NS, Kottke‐Marchant K, Lincoff AM, Tcheng JE, Sigmon KN, Joseph D, Rios G, Trainor K, Rose D, Greenberg CS, Kitt MM, Topol EJ, Califf RM: Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol 1995; 76: 1222–1227 [DOI] [PubMed] [Google Scholar]
  • 27. Kereiakes DJ, Kleiman NS, Ambrose J, Cohen M, Rodriguez S, Palabrica T, Herrmann HC, Sutton JM, Weaver WD, McKee DB, Fitzpatrick V, Sax FL: Randomized, double‐blind, placebo‐controlled dose ranging study of tirofiban (MK–383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol 1996; 27: 536–542 [DOI] [PubMed] [Google Scholar]
  • 28. Tcheng JE, Ellis SG, George BS, Kereiakes DJ, Kleiman NS, Talley JD, Wang AL, Weisman HF, Califf RM, Topol EJ: Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high‐risk coronary angioplasty. Circulation 1994; 90: 1757–1764 [DOI] [PubMed] [Google Scholar]
  • 29. Mascelli MA, Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE: Pharmacodynamic profile of short‐term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 1998; 97: 1680–1688 [DOI] [PubMed] [Google Scholar]
  • 30. Gammie JS, Zenati M, Kormos RL, Hattler BG, Wei LM, Pellegrini RV, Griffith BP, Dyke CM: Abciximab and excessive bleeding in patients undergoing emergency cardiac operations. Ann Thorac Surg 1998; 65: 465–469 [DOI] [PubMed] [Google Scholar]
  • 31. Tam SH, Sassoli PM, Jordan RE, Nakada MT: Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and αvb̃3 integrins. Circulation 1998; 98: 1085–1091 [DOI] [PubMed] [Google Scholar]
  • 32. Simon DI, Xu H, Ortlepp S, Rogers C, Rao NK: 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross‐reacts with the leukocyte integrin Mac‐1 and blocks adhesion to fibrinogen and ICAM‐1. Arterioscler Thromb Vasc Biol 1997; 17: 528–535 [DOI] [PubMed] [Google Scholar]
  • 33. Phillips DR, Scarborough RM: Clinical pharmacology of eptifibatide. Am J Cardiol 1997; 80: 11B–20B [DOI] [PubMed] [Google Scholar]
  • 34. Deckelbaum LI, Sax FL, Grossman W: Tirofiban, a nonpeptide inhibitor of the platelet glycoprotein IIb/IIIa receptor In New Therapeutic Agents in Thrombosis and Thrombolysis, p. 355–365 (Eds. Sasahara AA, Loscalzo J.). New York: Marcel Dekker, 1997. [Google Scholar]
  • 35. Faulds D, Sorkin EM: Abciximab (c7E3 Fab). A review of its pharmacology and therapeutic potential in ischaemic heart disease. Drugs 1994; 48: 583–598 [DOI] [PubMed] [Google Scholar]
  • 36. Tcheng JE, Kereiakes DJ, Braden GA, Lincoff AM, Mascelli MA, Langrall MA, Damaraju LV, Schantz AR, Barnathan ES, Effron MB: Safety of abciximab retreatment—final clinical report of the ReoPro Readministration Registry (R3) (abstr). Circulation 1998; 98 (suppl): I–17 [Google Scholar]
  • 37. Lincoff AM, Califf RM, Anderson KM, Weisman HF, Aguirre FV, Kleiman NS, Harrington RA, Topol EJ: Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. J Am Coll Cardiol 1997; 30: 149–156 [DOI] [PubMed] [Google Scholar]
  • 38. Klootwijk P, Meij S, Melkert R, Lenderink T, Simoons ML: Reduction of recurrent ischemia with abciximab during continuous ECG‐ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE). Circulation 1998; 98: 1358–1364 [DOI] [PubMed] [Google Scholar]
  • 39. Heeschen C, Hamm CW, Goldmann BU, Wohlrath S, Deu A, van der Wieken R: Recurrence of symptoms in patients with refractory unstable angina during treatment with abciximab before coronary revascularization—results from the CAPTURE trial (abstr). Circulation 1998; 98 (suppl): I–358 [Google Scholar]
  • 40. Hamm CW, Heeschen C, Goldmann B, Vahanian A, Adgey J, Miguel CM, Rutsch W, Berger J, Kootstra J, Simoons ML, for the c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators : Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. N Engl J Med 1999; 340: 1623–1629 [DOI] [PubMed] [Google Scholar]
  • 41. Ohman EM, Armstrong PW, Christenson RH, Granger CB, Katus HA, Hamm CW, O'Hanesian MA, Wagner GS, Kleiman NS, Harrell FE Jr, Califf RM, Topol EJ: Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med 1996; 335: 1333–1341 [DOI] [PubMed] [Google Scholar]
  • 42. Olatidoye AG, Wu AH, Feng YJ, Waters D: Prognostic role of troponin T versus troponin I in unstable angina pectoris for cardiac events with meta‐analysis comparing published studies. Am J Cardiol 1998; 81: 1405–1410 [DOI] [PubMed] [Google Scholar]
  • 43. Zhao X‐Q, Davis J, Barr E, Snapinn SM, Shaw WC, Sax FL, Théroux P: Presence of intracoronary thrombus predicts poor clinical outcomes in unstable angina/non‐Q‐wave myocardial infarction patients (abstr). Circulation 1998; 98 (suppl): I–492 [Google Scholar]
  • 44. Zhao X‐Q, Davis J, Deckelbaum LI, Barr E, Snapinn SM, Shaw WC, Sax FL, Théroux P: Impaired coronary perfusion is associated with worse clinical outcomes in unstable angina/non‐Q‐wave myocardial infarction patients (abstr). Circulation 1998; 98 (suppl): I–359–I–360 [Google Scholar]
  • 45. Harrington RA, Lincoff AM, Berdan LG, MacAulay C, Kint P‐P, Mahaffey KW, Kitt MM, Simoons ML, Califf RM: Maintenance of clinical benefit at six‐months in patients treated with the platelet glycoprotein IIb/IIIa inhibitor eptifibatide versus placebo during an acute ischemic coronary event (abstr). Circulation 1998; 98 (suppl): I–359 [Google Scholar]
  • 46. Lorenz TJ, Greenberg S, Kleiman NS, Boersma E, Lincoff MA, Harrington RA, Kitt MM, Simoons ML: Eptifibatide during immediate percutaneous coronary intervention (PCI) in the acute coronary syndromes (ACS): Findings from the PURSUIT study (abstr). J Am Coll Cardiol 1999; 33 (suppl A): 72A [Google Scholar]
  • 47. Antman EM, McCabe CH, Premmereur J, Gurfinkel E, Bemink PJLM, Turpie AGG, de Luna AB, LaBlanche J‐M, Fox KM, Salein D, Radley DR, Braunwald E: Enoxaparin for the acute and chronic management of unstable angina/non‐Q‐wave myocardial infarction: Results of TIMI 11B (abstr). Circulation 1998; 98 (suppl): 1–504 9665051 [Google Scholar]
  • 48. Antman EM, Cohen M, Radley D, McCabe CH, Premmereur J, Braunwald E: Enoxaparin for unstable angina/non‐Q‐wave myocardial infarction: Meta‐analysis of TIMI 11 B and ESSENCE (abstr). J Am Coll Cardiol 1999; 33 (suppl A): 351A [DOI] [PubMed] [Google Scholar]
  • 49. Greenbaum AB, Hudson MP, MacAulay CM, Berdan LG, Armstrong PW, Kleiman NS, Harrington RA: Time of events after hospitalization for acute coronary syndromes (abstr). Circulation 1998; 98 (suppl): I–630 [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES